What are the marketing complaints against Pfizer's Vyndamax?
Pfizer has been accused of describing Vyndamax as "the first and only approved treatment" after rivals were already on the market, and a German court ordered it to stop using "near-complete stabilisation" as a claim.
Critics allege that parts of Pfizer's Vyndamax promotion have been misleading. In September 2025 the company was publicly accused of showing a video at a medical meeting that described Vyndamax as the 'first and only approved treatment' for ATTR-CM - even though BridgeBio's Attruby and Alnylam's Amvuttra were already on the market. A separate Pfizer comparison of two drugs was also accused of not being based on fair and comparable standards.
A German court ruled that Pfizer must stop using 'near-complete stabilisation' to describe its therapy because the claim was unsupported by its data and label. In the US, patient advocates have questioned language presenting Vyndamax as the 'only' once-daily capsule for ATTR-CM. Separately, reporting noted that Pfizer gave $50,000 in 2016 to a patient group its materials refer patients to.